Subcellular distribution of protein phosphatases and abnormally phosphorylated τ in the temporal cortex from Alzheimer's disease and control brains

被引:0
|
作者
J.-J. Pei
C.-X. Gong
K. Iqbal
I. Grundke-Iqbal
Q. L. Wu
B. Winblad
R. F. Cowburn
机构
[1] Karolinska Institute,
[2] Department of Clinical Neuroscience and Family Medicine,undefined
[3] Section for Geriatric Medicine,undefined
[4] Novum,undefined
[5] KFC,undefined
[6] Huddinge,undefined
[7] Sweden,undefined
[8] NYS Institute for Basic Research in Developmental Disabilities,undefined
[9] Staten Island,undefined
[10] NY,undefined
[11] U.S.A.,undefined
来源
Journal of Neural Transmission | 1998年 / 105卷
关键词
Keywords: Protein phosphatases; AD P-tau; subcellular fractions; indirect enzyme-linked immunosorbent assay (ELISA); Alzheimer's disease.;
D O I
暂无
中图分类号
学科分类号
摘要
Microtubule-associated protein tau is abnormally hyperphosphorylated in the brain of patients with Alzheimer's disease (AD). In vitro studies have shown that protein phosphatases PP-2A and PP-2B can convert Alzheimer like tau to its normal state and that the activities of PP-1, PP-2A, and phosphotyrosyl-protein phosphatase (PTP) are reduced in AD brain. However, to have a direct effect on the regulation of phosphorylation on tau, these enzymes have to exist in neurons. Using specific polyclonal antibodies the levels of protein phosphatases PP-1, PP-2A, and PP-2B were determined by indirect ELISA in superior temporal cortical gray matter of AD and control brains. The protein levels of PP-2A and PP-2B were significantly increased in postsynaptosomal supernatant 2 (S2) of the AD group, and this alteration showed a significant linear correlation with levels of hyperphosphorylated tau. PP-1 and PTP-1B levels were not significantly changed in any of the AD fractions. Because of the large variation from case to case, the activity levels of none of the phosphatases investigated were significantly different between the AD and control groups. However, the PP-2B specific activity (activity/protein) showed a significant linear inverse correlation with hyperphosphorylated tau. These studies suggest that any attempt by the AD brain to compensate for the decreased tau phosphatase activity remains unsuccessful and that the decrease in phosphatase activity might contribute to increased levels of abnormally phosphorylated tau.
引用
收藏
页码:69 / 84
页数:15
相关论文
共 50 条
  • [41] Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative
    Zettergren, Anna
    Lord, Jodie
    Ashton, Nicholas J.
    Benedet, Andrea L.
    Karikari, Thomas K.
    Rodriguez, Juan Lantero
    Snellman, Anniina
    Suarez-Calvet, Marc
    Proitsi, Petroula
    Zetterberg, Henrik
    Blennow, Kaj
    ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)
  • [42] Quantitative proteomics of tau and Aβ in n detergent fractions from Alzheimer's disease brains
    Mukherjee, Soumya
    Dubois, Celine
    Perez, Keyla
    Varghese, Shiji
    Birchall, Ian E.
    Leckey, Miranda
    Davydova, Natalia
    McLean, Catriona
    Nisbet, Rebecca M.
    Roberts, Blaine R.
    Li, Qiao-Xin
    Masters, Colin L.
    Streltsov, Victor A.
    JOURNAL OF NEUROCHEMISTRY, 2023, 164 (04) : 529 - 552
  • [43] Global Electrophysiological Excitatory to Inhibitory Imbalance in Hippocampus and Temporal Cortex in the Continuum of Alzheimer's Disease
    Scaduto, Pietro
    Russell, William
    Limon, Agenor
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 299 - 300
  • [44] TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease
    Nag, Sukriti
    Yu, Lei
    Boyle, Patricia A.
    Leurgans, Sue E.
    Bennett, David A.
    Schneider, Julie A.
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2018, 6 : 33
  • [45] Global Electrophysiological Excitatory to Inhibitory Imbalance in Hippocampus and Temporal Cortex in the Continuum of Alzheimer's Disease
    Scaduto, Pietro
    Russell, William
    Limon, Agenor
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 299 - 300
  • [46] Protein Quality Control in Alzheimer's Disease: A Fatal Saviour
    Scheper, W.
    Hol, E. M.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2005, 4 (03) : 283 - 292
  • [47] TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease
    Sukriti Nag
    Lei Yu
    Patricia A. Boyle
    Sue E. Leurgans
    David A. Bennett
    Julie A. Schneider
    Acta Neuropathologica Communications, 6
  • [48] Biochemical Differentiation of Cholinesterases from Normal and Alzheimer's Disease Cortex
    Ciro, Alexis
    Park, Joon
    Burkhard, Gary
    Yan, Nicole
    Geula, Changiz
    CURRENT ALZHEIMER RESEARCH, 2012, 9 (01) : 138 - 143
  • [49] Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
    Anna Zettergren
    Jodie Lord
    Nicholas J. Ashton
    Andrea L. Benedet
    Thomas K. Karikari
    Juan Lantero Rodriguez
    Anniina Snellman
    Marc Suárez-Calvet
    Petroula Proitsi
    Henrik Zetterberg
    Kaj Blennow
    Alzheimer's Research & Therapy, 13
  • [50] Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome
    Shim, KS
    Lubec, G
    NEUROSCIENCE LETTERS, 2002, 324 (03) : 209 - 212